UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 714, 2025

Trevi Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

     Delaware

     001-38886

     45-0834299

     (State or Other Jurisdiction
of Incorporation)

     (Commission
File Number)

     (IRS Employer
Identification No.)

     195 Church Street, 16th Floor
New Haven, Connecticut

     06510

     (Address of Principal Executive Offices)

     (Zip Code)

Registrant’s telephone number, including area code: (203) 304-2499

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

     Title of each class

     Trading
symbol(s)

     Name of each exchange
on which registered

     Common stock, $0.001 par value per share

     TRVI

     The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.02 ~~Results~~Departure of ~~Operations~~Directors ~~and~~or ~~Financial~~Certain ~~Condition~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On August 714, 2025, Trevi Therapeutics, Inc., ~~a Delaware corporation~~ (the “Company”) ~~announced~~and ~~its~~Lisa ~~financial~~Delfini, ~~results for~~ the ~~quarter~~Company’s ~~ended~~Chief ~~June~~Financial 30Officer, ~~2025.~~agreed ~~The~~that ~~full~~her ~~text~~employment ofwith the ~~press~~Company ~~release~~would ~~issued~~end inon ~~connection~~August ~~with~~22, 2025 (the ~~announcement~~“Effective isDate”) ~~furnished~~and that she would resign as ~~Exhibit~~Chief 99Financial Officer.1 toThe ~~this~~Company ~~Current~~appreciates ~~Report~~the onservice ~~Form~~of ~~8-K~~Ms. Delfini and her resignation is ~~incorporated~~not ~~herein~~the byresult ~~reference.~~of any disagreement with the Company on any matter, including the Company’s operations, policies or practices.

~~The~~In ~~information~~connection ~~provided~~with ~~under~~the ~~Item~~end ~~2.02~~ of ~~this~~her ~~Form~~employment, ~~8-K~~the ~~(including~~Company ~~Exhibit~~has ~~99.1)~~agreed ~~shall~~to ~~not~~provide beMs. ~~deemed~~Delfini ~~“filed”~~the ~~for~~separation ~~purposes~~benefits ofprovided ~~Section~~under 18the ofCompany’s ~~the~~Executive ~~Securities~~Separation ~~Exchange~~Benefits ~~Act~~and ofRetention ~~1934~~Plan, assubject ~~amended~~to (the ~~“Exchange~~execution ~~Act”)~~by orMs. ~~otherwise~~Delfini ~~subject~~of toa ~~the~~severance ~~liabilities~~and release of ~~that~~claims ~~section~~agreement containing, ~~nor~~among ~~shall~~other itthings, bea ~~deemed~~general ~~incorporated~~release byof ~~reference~~claims, inan ~~any~~agreement ~~filing~~not ~~under~~to disparage the ~~Securities~~Company ~~Act~~and a reaffirmation of ~~1933~~her confidentiality, asnon-solicitation ~~amended,~~and ornon-compete ~~the~~obligations ~~Exchange~~under ~~Act,~~her ~~except~~existing asinvention ~~expressly~~and ~~set~~non-disclosure ~~forth~~agreement byand ~~specific~~non-competition ~~reference~~and innon-solicitation ~~such~~agreement awith ~~filing.~~the Company.

~~Item~~As 9of the Effective Date, Jennifer L.01 Good, the Company’s President and Chief Executive Officer, will serve as the Company’s principal financial officer on an interim basis until a new principal financial officer is designated. ~~Financial~~For ~~Statements~~Ms. Good’s biographical information, see the disclosure included under the headings “Proposal 1: Election of Two Class III Directors” and ~~Exhibits~~“Transactions with Related Persons” beginning on page 6 and page 36, respectively, of the Company’s Proxy Statement on Schedule 14A, filed with the SEC on April 29, 2025, which disclosure is incorporated herein by reference.

(d) Exhibits


Exhibit No.		Description

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Exhibit No.		Description
99.1		Press release issued by the Company on August 7, 2025*
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

* The exhibit shall be deemed to be furnished, and not filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TREVI THERAPEUTICS, INC.
Date: August 7, 2025	By:	/s/ Lisa Delfini
Date: August 20, 2025	By:	/s/ Jennifer L. Good
		Name: Lisa Delfini
		Name: Jennifer L. Good
		Title: Chief Financial Officer
		Title: President and Chief Executive Officer

Filing Compare · Trevi Therapeutics, Inc.